Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in the United States. Its principal product candidate, prGCD, is a proprietary plant cell expressed recombinant Glucocerebrosidase enzyme for the treatment of Gaucher disease, which has approval to commence phase III clinical trial. The company also develops PRX-102, a proprietary alpha Galactosidase enzyme for the treatment of Fabry disease, a genetic lysosomal storage disorder in humans, the symptoms of which involve the accumulation of lipids in the cells of the kidneys, heart, and other organs; a proprietary plant cell-based acetylcholinestrase and its molecular variants for use in various therapeutic indications, including a Biodefense program, as well as an organophosphate-based pesticide treatment program; and PRX-111, a human fertility hormone targeted at the female infertility market. Protalix BioTherapeutics has strategic collaboration with Teva Pharmaceutical Industries, Ltd. for the development and manufacturing of two proteins using the companyÂ’s ProCellEx protein expression system; and Yeda Research and Development Company Limited to design a next generation of Glucocerebrosidase for the treatment of Gaucher disease, as well as has a licensing agreement with Icon Genetics AG to license IconÂ’s amplification technology for utilization in the expression of its products. The company was founded in 1993 and is based in Carmiel, Israel
$2.04 (04/01/09)
